C. V. van Beurden-Tan

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis

P. Sonneveld, C. U. Uyl‐de Groot, S. Zweegman, 2019, Haematologica.

Reply to X. Armoiry et al.

P. Sonneveld, C. U. Uyl‐de Groot, M. Franken, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multinomial network meta-analysis using response rates: relapsed/refractory multiple myeloma treatment rankings differ depending on the choice of outcome

P. Sonneveld, C. D. Groot, C. V. van Beurden-Tan, 2022, BMC cancer.

Treatment Sequencing Survival Model for Patients with Multiple Myeloma Ineligible for Stem Cell Transplantation (SCT).

U. Mellqvist, H. Einsele, A. Palumbo, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.

P. Sonneveld, C. U. Uyl‐de Groot, M. Franken, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France

I. Majer, B. Brethon, A. Petit, 2023, PharmacoEconomics - Open.

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma

P. Sonneveld, P. Huijgens, C. U. Uyl‐de Groot, 2021, JAMA network open.